Hepatocyte growth factor and Met in drug discovery (Q38377273)

2 September 2017

1 reference

title

Hepatocyte growth factor and Met in drug discovery (English)

1 reference

2 September 2017

1 reference

2

Shunsuke Aoki

1 reference

2 September 2017

Katsuya Sakai

1

1 reference

2 September 2017

Kunio Matsumoto

series ordinal

3

1 reference

2 September 2017

language of work or name

1 reference

13 March 2015

1 reference

2 September 2017

published in

Journal of Biochemistry

1 reference

2 September 2017

volume

157

1 reference

2 September 2017

issue

5

1 reference

2 September 2017

page(s)

271-284

1 reference

Molecular cloning and expression of human hepatocyte growth factor

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Hepatocyte growth factor twenty years on: Much more than a growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Hepatocyte growth factor and its receptor signalling complex as targets in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Targeting the HGF/Met signaling pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Targeting MET in cancer: rationale and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Structural basis of hepatocyte growth factor/scatter factor and MET signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Cooperative interaction between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Essential role of Gab1 for signaling by the c-Met receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Bi-directional regulation of Ser-985 phosphorylation of c-met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Scatter factor/hepatocyte growth factor is essential for liver development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Met provides essential signals for liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Loss of c-Met accelerates development of liver fibrosis in response to CCl(4) exposure through deregulation of multiple molecular pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Deletion of the Met tyrosine kinase in liver progenitor oval cells increases sensitivity to apoptosis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Met and the epidermal growth factor receptor act cooperatively to regulate final nephron number and maintain collecting duct morphology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

c-Met is essential for wound healing in the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Beta-cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Targeted inactivation of hepatocyte growth factor receptor c-met in beta-cells leads to defective insulin secretion and GLUT-2 downregulation without alteration of beta-cell mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Disruption of hepatocyte growth factor/c-Met signaling enhances pancreatic beta-cell death and accelerates the onset of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Evidence of cell‐nonautonomous changes in dendrite and dendritic spine morphology in the met‐signaling–deficient mouse forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Circuit-specific intracortical hyperconnectivity in mice with deletion of the autism-associated Met receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

A new synaptic player leading to autism risk: Met receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

A genetic variant that disrupts MET transcription is associated with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Alternative proteolytic processing of hepatocyte growth factor during wound repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Diverse and potent activities of HGF/SF in skin wound repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Recombinant hepatocyte growth factor accelerates cutaneous wound healing in a diabetic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Hepatocyte growth factor may accelerate healing in chronic leg ulcers: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Human hepatocyte growth factor promotes functional recovery in primates after spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

The MET oncogene is a functional marker of a glioblastoma stem cell subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Wnt activity defines colon cancer stem cells and is regulated by the microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Technologies for the synthesis of mRNA-encoding libraries and discovery of bioactive natural product-inspired non-traditional macrocyclic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

Artificial human Met agonists based on macrocycle scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJB%2FMVV027

21 January 2018

Identifiers

DOI

10.1093/JB/MVV027

1 reference

2 September 2017

1 reference